Search

Your search keyword '"Wulf, Gerburg"' showing total 564 results
Start Over Author "Wulf, Gerburg"
564 results on '"Wulf, Gerburg"'

1. Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals

Author

Heng, Yujing J., Baker, Gabrielle M., Fein-Zachary, Valerie J., Guzman-Arocho, Yaileen D., Bret-Mounet, Vanessa C., Massicott, Erica S., Torous, Vanda F., Schnitt, Stuart J., Gitin, Sy, Russo, Paul, Tobias, Adam M., Bartlett, Richard A., Varma, Gopal, Kontos, Despina, Yaghjyan, Lusine, Irwig, Michael S., Potter, Jennifer E., and Wulf, Gerburg M.

Published
2024
Full Text
View/download PDF

2. Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry

Author

Ke, Shizhong, Dang, Fabin, Wang, Lin, Chen, Jia-Yun, Naik, Mandar T., Li, Wenxue, Thavamani, Abhishek, Kim, Nami, Naik, Nandita M., Sui, Huaxiu, Tang, Wei, Qiu, Chenxi, Koikawa, Kazuhiro, Batalini, Felipe, Stern Gatof, Emily, Isaza, Daniela Arango, Patel, Jaymin M., Wang, Xiaodong, Clohessy, John G., Heng, Yujing J., Lahav, Galit, Liu, Yansheng, Gray, Nathanael S., Zhou, Xiao Zhen, Wei, Wenyi, Wulf, Gerburg M., and Lu, Kun Ping

Published
2024
Full Text
View/download PDF

3. A 13C/31P surface coil to visualize metabolism and energetics in the rodent brain at 3 Tesla

Author

Vaidya, Manushka V, Zhang, Bei, Hong, DongHyun, Brown, Ryan, Batsios, Georgios, Viswanath, Pavithra, Paska, Jan, Wulf, Gerburg, Grant, Aaron K, Ronen, Sabrina M, and Larson, Peder EZ

Subjects
Medical and Biological Physics, Physical Sciences, Bioengineering, Cancer, Animals, Rats, Magnetic Resonance Imaging, Protons, Rodentia, Bicarbonates, Brain, Phantoms, Imaging, Pyruvic Acid, Lactates, Alanine, Adenosine Triphosphate, Equipment Design, Multinuclear RF coils, Hyperpolarized 13C MRS, Phosphorus MRS, Engineering, Biophysics, Physical sciences
Abstract

PurposeWe constructed a 13C/31P surface coil at 3 T for studying cancer metabolism and bioenergetics. In a single scan session, hyperpolarized 13C-pyruvate MRS and 31P MRS was carried out for a healthy rat brain.MethodsAll experiments were carried out at 3 Tesla. The multinuclear surface coil was designed as two coplanar loops each tuned to either the 13C or 31P operating frequency with an LCC trap on the 13C loop. A commercial volume proton coil was used for anatomical localization and B0 shimming. Single tuned coils operating at either the 13C or 31P frequency were built to evaluate the relative performance of the multinuclear coil. Coil performance metrics consisted of measuring Q factor ratio, calculating system input power using a single-pulse acquisition, and acquiring SNR and flip angle maps using 2D CSI sequences. To observe in vivo spectra, a bolus of hyperpolarized [1-13C] pyruvate was administered via tail vein. In vivo13C and endogenous 31P spectra were obtained in a single scan session using 1D slice selective acquisitions.ResultsWhen compared with single tuned surface coils, the multinuclear coil performance showed a decrease in Q factor ratio, SNR, and transmit efficiency. Flip angle maps showed adequate flip angles within the phantom when the transmit voltage was set using an external phantom. Results show good detection of 13C labeled lactate, alanine, and bicarbonate in addition to ATP from 31P MRS.ConclusionsThe coil enables obtaining complementary information within a scan session, thus reducing the number of trials and minimizing biological variability for studies of metabolism and bioenergetics.

Published
2022

8. Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach

Author

Petrosyan, Varduhi, Dobrolecki, Lacey E., Thistlethwaite, Lillian, Lewis, Alaina N., Sallas, Christina, Srinivasan, Ramakrishnan R., Lei, Jonathan T., Kovacevic, Vladimir, Obradovic, Predrag, Ellis, Matthew J., Osborne, C. Kent, Rimawi, Mothaffar F., Pavlick, Anne, Shafaee, Maryam Nemati, Dowst, Heidi, Jain, Antrix, Saltzman, Alexander B., Malovannaya, Anna, Marangoni, Elisabetta, Welm, Alana L., Welm, Bryan E., Li, Shunqiang, Wulf, Gerburg M., Sonzogni, Olmo, Huang, Chen, Vasaikar, Suhas, Hilsenbeck, Susan G., Zhang, Bing, Milosavljevic, Aleksandar, and Lewis, Michael T.

Published
2023
Full Text
View/download PDF

9. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature

Author

Batalini, Felipe, Madison, Russell W., Sokol, Ethan S., Jin, Dexter X., Chen, Kuei-Ting, Decker, Brennan, Pavlick, Dean C., Frampton, Garrett M., Wulf, Gerburg M., Garber, Judy E., Oxnard, Geoffrey, Schrock, Alexa B., and Tung, Nadine M.

Published
2023
Full Text
View/download PDF

10. PARP-inhibition reprograms macrophages toward an anti-tumor phenotype

Author

Wang, Lin, Wang, Dan, Sonzogni, Olmo, Ke, Shizhong, Wang, Qi, Thavamani, Abhishek, Batalini, Felipe, Stopka, Sylwia A., Regan, Michael S., Vandal, Steven, Tian, Shengya, Pinto, Jocelin, Cyr, Andrew M., Bret-Mounet, Vanessa C., Baquer, Gerard, Eikesdal, Hans P., Yuan, Min, Asara, John M., Heng, Yujing J., Bai, Peter, Agar, Nathalie Y.R., and Wulf, Gerburg M.

Published
2022
Full Text
View/download PDF

13. MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Author

Gounder, Mrinal, Johnson, Melissa, Heist, Rebecca S., Shapiro, Geoffrey I., Postel-Vinay, Sophie, Wilson, Frederick H., Garralda, Elena, Wulf, Gerburg, Almon, Caroline, Nabhan, Salah, Aguado-Fraile, Elia, He, Peng, Romagnoli, Mathilde, Hossain, Mohammad, Narayanaswamy, Rohini, Sadou-Dubourgnoux, Amel, Cooper, Michael, Askoxylakis, Vasileios, Burris, Howard A., and Tabernero, Josep

Subjects
LIVER function tests, ADENOSYLMETHIONINE, PHARMACOKINETICS, METHIONINE, THROMBOCYTOPENIA
Abstract

Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.gov Identifier: NCT03435250). Eligible patients had tumors with homozygous deletion of CDKN2A/MTAP and/or loss of MTAP protein by immunohistochemistry. Patients received AG-270/S095033 once daily (QD) or twice daily (BID) in 28-day cycles. The primary objective was to assess the maximum tolerated dose (MTD) of AG-270/S095033. Secondary objectives included safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy. Forty patients were treated with AG-270/S095033. Plasma concentrations of AG-270/S095033 increased with dose. Maximal reductions in plasma SAM concentrations ranged from 54% to 70%. Analysis of paired tumor biopsies showed decreases in levels of symmetrically di-methylated arginine (SDMA) residues. Reversible increases in liver function tests, thrombocytopenia, anemia and fatigue were common treatment-related toxicities. Two partial responses were observed; five additional patients achieved radiographically confirmed stable disease for ≥16 weeks. AG-270/S095033 has a manageable safety profile. Our data provide preliminary evidence of clinical activity and proof-of-mechanism for MAT2A inhibition. AG-270 inhibited the activity of MAT2A and reduced plasma concentrations of SAM by up to 70% in patients with advanced solid tumors. Partial responses were observed in two patients and disease stabilization for ≥4 months was seen in five patients. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

15. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy

Author

Koikawa, Kazuhiro, Kibe, Shin, Suizu, Futoshi, Sekino, Nobufumi, Kim, Nami, Manz, Theresa D., Pinch, Benika J., Akshinthala, Dipikaa, Verma, Ana, Gaglia, Giorgio, Nezu, Yutaka, Ke, Shizhong, Qiu, Chenxi, Ohuchida, Kenoki, Oda, Yoshinao, Lee, Tae Ho, Wegiel, Babara, Clohessy, John G., London, Nir, Santagata, Sandro, Wulf, Gerburg M., Hidalgo, Manuel, Muthuswamy, Senthil K., Nakamura, Masafumi, Gray, Nathanael S., Zhou, Xiao Zhen, and Lu, Kun Ping

Published
2021
Full Text
View/download PDF

18. Supplementary Table S1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

19. FIGURE 5 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

20. FIGURE 4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

22. FIGURE 6 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

23. FIGURE 1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

24. FIGURE 2 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

25. FIGURE 3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

26. Data from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Author

Guo, Zhanfang, primary, Luo, Jingqin, primary, Mashl, R. Jay, primary, Hoog, Jeremy, primary, Maiti, Piyush, primary, Fettig, Nikki, primary, Davies, Sherri R., primary, Aft, Rebecca, primary, Held, Jason M., primary, Govindan, Ramaswamy, primary, Ding, Li, primary, Li, Shunqiang, primary, von Morze, Cornelius, primary, Wulf, Gerburg M., primary, Shoghi, Kooresh I., primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

27. TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.

Author

Tung, Nadine M., primary, Robson, Mark E., additional, Nanda, Rita, additional, Li, Tianyu, additional, Vinayak, Shaveta, additional, Shah, Payal Deepak, additional, Khoury, Katia, additional, Kimmick, Gretchen Genevieve, additional, Santa-Maria, Cesar Augusto, additional, Brufsky, Adam, additional, DeMeo, Michelle, additional, Vieira, Joao Pedro, additional, Carey, Lisa A., additional, Wulf, Gerburg M., additional, Domchek, Susan M., additional, Krop, Ian E., additional, Wolff, Antonio C., additional, Winer, Eric P., additional, and Garber, Judy Ellen, additional

Published
2024
Full Text
View/download PDF

29. Evaluation of copanlisib in combination with eribulin in triple negative breast cancer patient-derived xenograft models

Author

Guo, Zhanfang, primary, Luo, Jingqin, additional, Mashl, R. Jay, additional, Hoog, Jeremy, additional, Maiti, Piyush, additional, Fettig, Nikki, additional, Davies, Sherri R., additional, Aft, Rebecca, additional, Held, Jason M., additional, Govindan, Ramaswamy, additional, Ding, Li, additional, Li, Shunqiang, additional, von Morze, Cornelius, additional, Wulf, Gerburg M., additional, Shoghi, Kooresh I., additional, and Ma, Cynthia X., additional

Published
2024
Full Text
View/download PDF

30. Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton

Author

Hu, Hai, Juvekar, Ashish, Lyssiotis, Costas A, Lien, Evan C, Albeck, John G, Oh, Doogie, Varma, Gopal, Hung, Yin Pun, Ullas, Soumya, Lauring, Josh, Seth, Pankaj, Lundquist, Mark R, Tolan, Dean R, Grant, Aaron K, Needleman, Daniel J, Asara, John M, Cantley, Lewis C, and Wulf, Gerburg M

Subjects
Underpinning research, 1.1 Normal biological development and functioning, Animals, Breast Neoplasms, Cell Line, Tumor, Cytoskeleton, Cytosol, Disease Models, Animal, Epithelial Cells, Fructose-Bisphosphate Aldolase, Glycolysis, Humans, Insulin, Mice, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Signal Transduction, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

The phosphoinositide 3-kinase (PI3K) pathway regulates multiple steps in glucose metabolism and also cytoskeletal functions, such as cell movement and attachment. Here, we show that PI3K directly coordinates glycolysis with cytoskeletal dynamics in an AKT-independent manner. Growth factors or insulin stimulate the PI3K-dependent activation of Rac, leading to disruption of the actin cytoskeleton, release of filamentous actin-bound aldolase A, and an increase in aldolase activity. Consistently, PI3K inhibitors, but not AKT, SGK, or mTOR inhibitors, cause a significant decrease in glycolysis at the step catalyzed by aldolase, while activating PIK3CA mutations have the opposite effect. These results point toward a master regulatory function of PI3K that integrates an epithelial cell's metabolism and its form, shape, and function, coordinating glycolysis with the energy-intensive dynamics of actin remodeling.

Published
2016

31. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Author

Konstantinopoulos, Panagiotis A, Barry, William T, Birrer, Michael, Westin, Shannon N, Cadoo, Karen A, Shapiro, Geoffrey I, Mayer, Erica L, O'Cearbhaill, Roisin E, Coleman, Robert L, Kochupurakkal, Bose, Whalen, Christin, Curtis, Jennifer, Farooq, Sarah, Luo, Weixiu, Eismann, Julia, Buss, Mary K, Aghajanian, Carol, Mills, Gordon B, Palakurthi, Sangeetha, Kirschmeier, Paul, Liu, Joyce, Cantley, Lewis C, Kaufmann, Scott H, Swisher, Elizabeth M, D'Andrea, Alan D, Winer, Eric, Wulf, Gerburg M, and Matulonis, Ursula A

Published
2019
Full Text
View/download PDF

33. Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals.

Author

Heng, Yu Jing Jan, primary, Baker, Gabrielle M, additional, Fein-Zachary, Valerie J, additional, Guzman-Arocho, Yaileen D, additional, Bret-Mounet, Vanessa C, additional, Massicott, Erica S, additional, Gitin, Sy, additional, Russo, Paul, additional, Tobias, Adam M, additional, Bartlett, Richard A, additional, Varma, Gopal, additional, Kontos, Despina, additional, Yaghjyan, Lusine, additional, Irwig, Michael S, additional, Potter, Jennifer E, additional, and Wulf, Gerburg M, additional

Published
2024
Full Text
View/download PDF

34. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Author

Keenan, Tanya E., Guerriero, Jennifer L., Barroso-Sousa, Romualdo, Li, Tianyu, O’Meara, Tess, Giobbie-Hurder, Anita, Tayob, Nabihah, Hu, Jiani, Severgnini, Mariano, Agudo, Judith, Vaz-Luis, Ines, Anderson, Leilani, Attaya, Victoria, Park, Jihye, Conway, Jake, He, Meng Xiao, Reardon, Brendan, Shannon, Erin, Wulf, Gerburg, Spring, Laura M., Jeselsohn, Rinath, Krop, Ian, Lin, Nancy U., Partridge, Ann, Winer, Eric P., Mittendorf, Elizabeth A., Liu, David, Van Allen, Eliezer M., and Tolaney, Sara M.

Published
2021
Full Text
View/download PDF

37. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

Author

Varkaris, Andreas, primary, Fece de la Cruz, Ferran, additional, Martin, Elizabeth E., additional, Norden, Bryanna L., additional, Chevalier, Nicholas, additional, Kehlmann, Allison M., additional, Leshchiner, Ignaty, additional, Barnes, Haley, additional, Ehnstrom, Sara, additional, Stavridi, Anastasia-Maria, additional, Yuan, Xin, additional, Kim, Janice S., additional, Ellis, Haley, additional, Papatheodoridi, Alkistis, additional, Gunaydin, Hakan, additional, Danysh, Brian P., additional, Parida, Laxmi, additional, Sanidas, Ioannis, additional, Ji, Yongli, additional, Lau, Kayao, additional, Wulf, Gerburg M., additional, Bardia, Aditya, additional, Spring, Laura M., additional, Isakoff, Steven J., additional, Lennerz, Jochen K., additional, Del Vecchio, Kathryn, additional, Pierce, Levi, additional, Pazolli, Ermira, additional, Getz, Gad, additional, Corcoran, Ryan B., additional, and Juric, Dejan, additional

Published
2023
Full Text
View/download PDF

39. WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models

Author

Kishikawa, Takahiro, Higuchi, Hiroshi, Wang, Limei, Panch, Nivedita, Maymi, Valerie, Best, Sachem, Lee, Samuel, Notoya, Genso, Toker, Alex, Matesic, Lydia E., Wulf, Gerburg M., Wei, Wenyi, Otsuka, Motoyuki, Koike, Kazuhiko, Clohessy, John G., Lee, Yu-Ru, and Pandolfi, Pier Paolo

Subjects
Care and treatment, Development and progression, Genetic aspects, Health aspects, Phosphotransferases -- Health aspects, Gene mutation -- Health aspects, Breast cancer -- Genetic aspects -- Development and progression -- Care and treatment, Gene mutations -- Health aspects
Abstract

Introduction Phosphatidylinositol 3-kinases (PI3Ks) play a critical role in regulating various biological functions, including cell growth, survival, differentiation, metabolism, and motility. Dysregulation of the PI3K signaling pathway is one of [...], Activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is a pervasive event in tumorigenesis due to PI3K mutation and dysfunction of phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Pharmacological inhibition of PI3K has resulted in variable clinical outcomes, however, raising questions regarding the possible mechanisms of unresponsiveness and resistance to treatment. WWP1 is an oncogenic HECT-type ubiquitin E3 ligase frequently amplified and mutated in multiple cancers, as well as in the germ lines of patients predisposed to cancer, and was recently found to activate PI3K signaling through PTEN inactivation. Here, we demonstrate that PTEN dissociated from the plasma membrane upon treatment with PI3K inhibitors through WWP1 activation, whereas WWP1 genetic or pharmacological inhibition restored PTEN membrane localization, synergizing with PI3K inhibitors to suppress tumor growth both in vitro and in vivo. Furthermore, we demonstrate that WWP1 inhibition attenuated hyperglycemia and the consequent insulin feedback, which is a major tumor-promoting side effect of PI3K inhibitors. Mechanistically, we found that AMPKa2 was ubiquitinated and, in turn, inhibited in its activatory phosphorylation by WWP1, whereas WWP1 inhibition facilitated AMPK[alpha]2 activity in the muscle to compensate for the reduction in glucose uptake observed upon PI3K inhibition. Thus, our identification of the cell-autonomous and systemic roles of WWP1 inhibition expands the therapeutic potential of PI3K inhibitors and reveals new avenues of combination cancer therapy.

Published
2021
Full Text
View/download PDF

46. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Author

Xing, Yan, Lin, Nancy U., Maurer, Matthew A., Chen, Huiqin, Mahvash, Armeen, Sahin, Aysegul, Akcakanat, Argun, Li, Yisheng, Abramson, Vandana, Litton, Jennifer, Chavez-MacGregor, Mariana, Valero, Vicente, Piha-Paul, Sarina A., Hong, David, Do, Kim-Anh, Tarco, Emily, Riall, Dianna, Eterovic, Agda Karina, Wulf, Gerburg M., Cantley, Lewis C., Mills, Gordon B., Doyle, L. Austin, Winer, Eric, Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana Maria, and Meric-Bernstam, Funda

Published
2019
Full Text
View/download PDF

47. Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial

Author

Fanucci, Kristina A., primary, Pilat, Mary Jo, additional, Shyr, Derek, additional, Shyr, Yu, additional, Boerner, Scott A., additional, Durecki, Diane, additional, Noonan, Anne, additional, Abramson, Vandana, additional, Santa-Maria, Cesar, additional, Han, Hyo, additional, Nanda, Rita, additional, Dees, Elizabeth Claire, additional, Park, Haeseong, additional, Buys, Saundra, additional, Peswani, Namrata, additional, Chew, Helen, additional, Assad, Hadeel, additional, Wulf, Gerburg, additional, Richardson, Angelique, additional, Trivedi, Meghna S., additional, Brufsky, Adam, additional, Abbruzzese, James, additional, Afghahi, Anosheh, additional, Sharon, Elad, additional, Schalper, Kurt, additional, and LoRusso, Patricia, additional

Published
2023
Full Text
View/download PDF

48. Abstract 6190: Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers

Author

Patterson-Fortin, Jeffrey, primary, Jadhav, Heta, additional, Pantelidou, Constantia, additional, Phan, Tin, additional, Grochala, Carter, additional, Mehta, Anita K., additional, Guerriero, Jennifer L., additional, Wulf, Gerburg M., additional, Wolpin, Brian M., additional, Stanger, Ben Z., additional, Aguirre, Andrew J., additional, Cleary, James M., additional, D'Andrea, Alan D., additional, and Shapiro, Geoffrey I., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results